Preclinical characterization of a Selective FGFR2/3 inhibitor, GSC000829

被引：0
|
作者：
Han, T. [1 ]
Fu, D. [1 ]
Cheng, T. [1 ]
Xia, Y. [1 ]
Hu, Z. [1 ]
Yang, F. [1 ]
机构：
[1] Changchun GeneSci Pharmaceut Co Ltd, Chem Drug Res & Dev, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114647
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB112
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [41] Fgfr2 and Fgfr3 are not required for patterning and maintenance of the midbrain and anterior hindbrain
    Blak, Alexandra A.
    Naserke, Thorsten
    Saarimaki-Vire, Jonna
    Peltopuro, Paula
    Giraldo-Velasquez, Mario
    Weisenhorn, Daniela M. Vogt
    Prakash, Nilima
    Sendtner, Michael
    Partanen, Juha
    Wurst, Wolfgang
    DEVELOPMENTAL BIOLOGY, 2007, 303 (01) : 231 - 243
  • [42] Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
    Tyhonas, John S.
    Arnold, Lee D.
    Cox, Jason M.
    Franovic, Aleksandra
    Gardiner, Elisabeth
    Grandinetti, Kathryn
    Kania, Robert
    Kanouni, Toufike
    Lardy, Matthew
    Li, Chun
    Martin, Eric S.
    Miller, Nichol
    Mohan, Adithi
    Murphy, Eric A.
    Perez, Michelle
    Soroceanu, Liliana
    Timple, Noel
    Uryu, Sean
    Womble, Scott
    Kaldor, Stephen W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1734 - 1746
  • [43] Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
    Schram, Alison M.
    Subbiah, Vivek
    Liao, Chih-Yi
    Moreno, Victor
    Desamparados, Roda
    Ponz-Sarvise, Mariano
    Dotan, Efrat
    Cassier, Philippe Alexandre
    Moreno, Irene
    Varkaris, Andreas
    Kim, Richard D.
    Garralda, Elena
    Opdam, Frans
    Tai, David
    Italiano, Antoine
    Oh, Do-Youn
    Goyal, Lipika
    Fontana, Elise
    Liu, Jia
    Boukovala, Myrto
    Ghiringelli, Francois
    Borad, Mitesh J.
    Babiker, Hani
    Jin, Zhaohui
    Millward, Michael
    Yachnin, Jeffrey
    Kamath, Suneel Deepak
    Coward, Jermaine M.
    Yoo, Changhoon
    Kelley, Robin Kate
    Sahai, Vaibhav
    Bridgewater, John
    Springfield, Christoph
    Florou, Vaia
    El-Khoueiry, Anthony
    Eskens, Ferry
    Lin, Bruce
    Paulson, Scott
    Curigliano, Giuseppe
    Murphy, Meredith
    Deary, Alicia
    Ricard, Fabien
    Jen, Kai Yu
    Ramirez, Florence
    Blakesley, Rick E.
    Schmidt-Kittler, Oleg
    Mar, Brenton G.
    Park, Joon Oh
    Hollebecque, Antoine
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [44] Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance
    Wang, Yazhou
    Zhang, Yihong
    Liu, Jinxin
    Zhao, Jichen
    Wang, Chao
    Meng, Fanye
    Cai, Xin
    Zhang, Man
    Aliper, Alex
    Liang, Tao
    Yan, Feng
    Ren, Feng
    Lan, Jiong
    Lu, Qiang
    Zhou, Fusheng
    Zhavoronkov, Alex
    Ding, Xiao
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 3886 - 3899
  • [45] A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Xu, Jianming
    Xiong, Jianping
    Gu, Shanzhi
    Niu, Zuoxing
    Yin, Fei
    Sun, Beicheng
    Zhang, Lan
    Zhou, Fuxiang
    Hao, Chunyi
    Pan, Yueyin
    Qiu, Wensheng
    Gao, Yi
    Ren, Yongxin
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling
    Silverman, Ian M.
    Li, Meijuan
    Murugesan, Karthikeyan
    Krook, Melanie A.
    Javle, Milind M.
    Kelley, Robin K.
    Borad, Mitesh J.
    Roychowdhury, Sameek
    Meng, Wei
    Yilmazel, Bahar
    Milbury, Coren
    Shewale, Shantanu
    Feliz, Luis
    Burn, Timothy C.
    Albacker, Lee A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (04): : 351 - 364
  • [47] Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line
    Goriely, A
    McVean, GAT
    Röjmyr, M
    Ingemarsson, B
    Wilkie, AOM
    SCIENCE, 2003, 301 (5633) : 643 - 646
  • [48] EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma
    Wu, Qibiao
    Zhen, Yuanli
    Shi, Lei
    Vu, Phuong
    Greninger, Patricia
    Adil, Ramzi
    Merritt, Joshua
    Egan, Regina
    Wu, Meng-Ju
    Yin, Xunqin
    Ferrone, Cristina R.
    Deshpande, Vikram
    Baiev, Islam
    Pinto, Christopher J.
    McLoughlin, Daniel E.
    Walmsley, Charlotte S.
    Stone, James R.
    Gordan, John D.
    Zhu, Andrew X.
    Juric, Dejan
    Goyal, Lipika
    Benes, Cyril H.
    Bardeesy, Nabeel
    CANCER DISCOVERY, 2022, 12 (05) : 1378 - 1395
  • [49] Characterization of the intronic splicing silencers flanking FGFR2 exon IIIb
    Wagner, EJ
    Baraniak, AP
    Sessions, OM
    Mauger, D
    Moskowitz, E
    Garcia-Blanco, MA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (14) : 14017 - 14027
  • [50] Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer
    Ma, Lin
    Li, Yingying
    Luo, Ruixiang
    Wang, Yuhan
    Cao, Jiaqi
    Fu, Weitao
    Qian, Bolan
    Zheng, Lei
    Tang, Longguang
    Lv, Xinting
    Zheng, Lulu
    Liang, Guang
    Chen, Lingfeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (11) : 7438 - 7453
12345